title: Efalizumab-associated Guillain-Barre syndrome.
authors.forename: Frank
authors.initials: F
authors.lastname: Victor
authors.forename: Kavita
authors.initials: K
authors.lastname: Menon
authors.forename: Jo-Ann M
authors.initials: JA
authors.lastname: Latkowski
authors.forename: Adolfo
authors.initials: A
authors.lastname: Fernandez-Obregon
authors.forename: Bruce E
authors.initials: BE
authors.lastname: Strober
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D020275:Guillain-Barre Syndrome / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage; D007262:Infusions, Intravenous; D008297:Male; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy*; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007136:Immunoglobulins; C472181:efalizumab